Princeton, NJ, January 23, 2024 ─ iQure Pharma Inc. (iQure), a US-based global biotech, announced that its asset, iQ-008, a novel analgesic compound dedicated to treating neuropathic pain, has been awarded a patent.
“We are thrilled with the patent granted for iQ-008,” said iQure Chief Executive Officer Pawel Zolnierczyk. “This is an important step in the process of commercializing this promising asset for the treatment of Pain. Patent protection is pivotal to maintaining the value of our assets. With the awarding of this patent, we have expanded its protection and strengthened its potential on the market.”
iQ-008 is effective in critical in vivo studies against the “gold-standard,” but without the typical CNS side effects. Through its unique mechanism, focused on simultaneous action on more than one pain relevant molecular target, iQ-008 displays strong efficacy with minimal risk of side effects. The compound is also being vigorously tested by the NIH in its high profile Preclinical Screening Platform for Pain (PSPP), as part of the HEAL Initiative.
iQure researchers developed iQ-008 as a therapeutic for neuropathic pain, in response to the more than 25 million Americans who live with chronic pain and are forced to rely solely on potentially addictive opioid medications for pain management.
About iQure Pharma:
iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies based on a revolutionary glutamate-clearance platform for treating neurodegenerative conditions including neuro-inflammation.
For further information, please contact pawel.zolnierczyk@iqurepharma.com.